Tempo doses first patient with tissue scaffolds in cancer surgery trial [Yahoo! Finance]
COLOPLAST AS SP/ADR (CLPBY)
NASDAQ:AMEX Investor Relations:
coloplast.com/investor-relations
Company Research
Source: Yahoo! Finance
TT101 is an integrative scaffold with soft tissue regeneration potential. The study is aimed to evaluate the safety of TT01 and gather data on the product's ability to “regrow large volumes of surgically removed tissue”.Proceeds from a $12m Series A financing round raised in March are funding the clinical trial. The investment round was led by Johnson & Johnson Innovation (JJDC) and Galaxy Sirius Partners. TT101 isdeveloped using microporous annealed particle (MAP) technology that repurposes hydrogel polymer components to make a hyper-porous, flowable scaffold format. The technology is expected to allow for immediate tissue growth and integration, whilst not triggering inflammatory and scar-forming foreign body response. Tempo noted that the TT101 has “demonstrated non-immunogenic and regenerative tissue responses” in preclinical animal studies on soft tissue repair. The US-based company is developing TT101 for soft tissue regeneration and repair of complex surgical sites with ex
Show less
Read more
Impact Snapshot
Event Time:
CLPBY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CLPBY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CLPBY alerts
High impacting COLOPLAST AS SP/ADR news events
Weekly update
A roundup of the hottest topics
CLPBY
News
- Coloplast A/S (OTCMKTS: CLPBY) was upgraded by analysts at Hsbc Global Res from a "moderate sell" rating to a "hold" rating.MarketBeat
- North America Ostomy Drainage Bags (Colostomy, Ileostomy, and Urostomy) Market Outlook 2023-2024 & 2028 with Competitive Analysis of Coloplast, ConvaTec, B. Braun, Hollister, and Salts Healthcare [Yahoo! Finance]Yahoo! Finance
- CMS Confirms Coverage of Kerecis Fish-Skin Products by Medicare [Yahoo! Finance]Yahoo! Finance
- Kerecis included on the list of covered products for Diabetic Foot Ulcers in the final LCD policy [Yahoo! Finance]Yahoo! Finance
- Change in management board [Yahoo! Finance]Yahoo! Finance